Searched for
CHIKALTHANA PLANT
Wockhardt's Chikalthana plant still under import alert, says USFDAAn import alert means that the drugs manufactured at the plant cannot be sold in the US markets.- Wockhardt shares down 4.5% on boursesThe company's three facilities - Chikalthana and two units at Waluj in Maharashtra - have received EIR with observations, Wockhardt said in...
- USFDA observations for Shendra facility not critical: WockhardtChairman Habil Khorakiwala said the company will be able to make the facility compliant for half the issues in next fifteen days.
- Wockhardt's Chikalthana plant gets GMP certificate from UKMHRAIn a major relief to drug firm Wockhardt, its Chikalthana plant at Aurangabad in Maharashtra has received a good manufacturing practice cer...
- Wockhardt shares up 3% as UK MHRA makes no critical observationsShares of drug firm Wockhardt today surged 3 per cent after the company said the UK health regulator MHRA has completed inspection of its p...
- Wockhardt climbs 4% after MHRA completes plant inspectionThe stock jumped 3.65% to hit a high of Rs 1,597.15 on the exchange. Still, the stock is trading 20% lower from its all-time high of Rs 2,0...
- UK MHRA completes inspection of Wockhardt's Chikalthana plantWockhardt said the UK health regulator has completed inspection of its plant at Chikalthana without issuing any critical observations on th...
- Wockhardt surges 11% as USFDA completes inspection in two Maharashtra plantsWockhardt Ltd closed the day on BSE at Rs 1,575.05; up 10.67%. The stock surged as much as 11.57 per cent in intraday trade after reports t...
- Wockhardt plunges as firm to recall drugs from US marketThe company announced it is recalling some drugs from the US markets that were manufactured at its Chikalthana plant in Aurangabad.
- US FDA did not find issues with Wockhardt's Chikalthana plant"There were no findings with respect to data security and control measures in laboratory and manufacturing," Wockhardt said in a BSE filing.
- Addressing USFDA concerns over Waluj unit, says WockhardtUS Food and Drug Administration conducted inspection for about a week, he said there were no serious observation and nothing on data integr...
- Regulatory relief, exports boost Wockhardt shares by over 30 per centUK drug regulator cleared its Chikalthana facility; the company has also resolved its compliance-related issues at the Illinois facility.
- Why multibagger Wockhardt is on analysts' 'sell' radar nowFundamental troubles or the regulatory problems are not going to go away in a hurry for Wockhardt and it has become more of a trading stock...
- Brokerages lower Wockhardt's target price after USFDA import alert on Chikalthana plantThe USFDA import alert on Wockhardt's second plant will have a negative impact on the pharma major, say brokerages.
- Wockhardt extends overnight losses post import alertShares of Wockhardt extended losses for second consecutive session as sentiment turned bearish in the counter after the USFDA issued import...
- Wockhardt revenues may dip up to $250 m on USFDA banWockhardt may suffer an annual revenue fall of up to $250 million and its American operations may grind to a halt.
- Wockhardt's Chikalthana plant hit by USFDA import restrictionsIn May, the USFDA had also issued an import alert on the company's Waluj facility which makes injectables and solid dosages.
- Wockhardt plunges 14% as USFDA issues import alert on Chikalthana PlantThe Chikalthana facility received ‘483’ observations after the USFDA raised several concerns. This is the second plant in India to get impo...
- Wockhardt drops 5%, locked in lower circuit as UK health regulator withdraws certificationThe stock is now locked in lower circuit at Rs 499.30. It has lost nearly 10% in the month of October as compared to over 60% fall so far i...
- UK health regulator withdraws certification of Wockhardt unitThe impact of the same on existing business will only be known once the company receives further communication from UKMHRA, Wockhardt said.
Load More
